Table 5. Metabolite screen in serum between TA and CA.
| ID | Retention time | Mass | Mean of peak area | VIP | P | Direction change | |
|---|---|---|---|---|---|---|---|
| TA | CA | ||||||
| 1-methylnicotinamide | 337.65 | 137.07 | 2.16 | 1.11 | 2.16 | 0.02 | ↑ |
| L-palmitoylcarnitine | 199.12 | 400.34 | 1.33 | 0.88 | 1.67 | 0.04 | ↑ |
| 1-Nitrohexane | 71.59 | 132.10 | 0.08 | 0.13 | 1.17 | 0.04 | ↓ |
| Panaquinquecol 1 | 29.54 | 293.21 | 0.05 | 0.02 | 2.05 | 0.01 | ↑ |
| LysoPE(16:0/0:0) | 226.72 | 454.29 | 0.56 | 0.39 | 1.68 | 0.02 | ↑ |
| Glycylproline | 321.53 | 173.09 | 2.61 | 1.36 | 1.65 | 0.02 | ↑ |
| 5,6-trans-25-Hydroxyvitamin D3 | 106.77 | 401.34 | 0.010 | 0.014 | 1.56 | 0.04 | ↓ |
| Levetiracetam | 285.38 | 171.11 | 0.18 | 0.23 | 1.69 | 0.04 | ↓ |
| Monoglucuronylglycyrrhetinic acid | 317.04 | 647.38 | 0.13 | 0.03 | 1.92 | 0.048 | ↑ |
| Heptadecanoyl carnitine | 196.88 | 414.36 | 0.014 | 0.007 | 1.58 | 0.04 | ↑ |
| Stigmastane-3,6-dione | 149.98 | 429.37 | 0.52 | 0.20 | 2.06 | 0.02 | ↑ |
| PC (20:4(8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z)) | 158.82 | 832.58 | 2.20 | 1.82 | 1.13 | 0.03 | ↑ |
| Elaidic carnitine | 195.62 | 426.36 | 1.25 | 0.72 | 1.70 | 0.04 | ↓ |
| alpha-tocopherolquinone | 150.74 | 447.38 | 0.05 | 0.01 | 2.04 | 0.02 | ↑ |
| PC (22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:1(11Z)) | 157.08 | 860.61 | 0.20 | 0.16 | 1.15 | 0.01 | ↑ |
| Naphthoherniarin | 196.06 | 377.10 | 0.004 | 0.001 | 1.88 | 0.04 | ↑ |
Mean peak of area, the average value of peak area normalization for each group; TA, treatment group after surgery for 7 days in serum; CA, control group after surgery for 7 days in serum; VIP, variable importance projection; P, student t-test, considered as significance when <0.05.